Project: Development of a novel allosteric modulator to treat post-traumatic stress disorder
| Acronym | DiSARM FEAR (Reference Number: 113468) |
| Duration | 15/10/2019 - 17/10/2022 |
| Project Topic | The consortium will deliver DiSARM FEAR, a novel clinical candidate for Post-Traumatic Stress Disorder (PTSD), by developing small-molecule negative allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 7 (mGluR7) to reduce fear memory reconsolidation. We will generate a lead and perform pharmacology, ADME/PK, non-GLP toxicity and efficacy studies in new PTSD models. After the project, DiSARM FEAR will complete preclinical development and enter clinical trials. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 11 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Addex Pharma SA | Coordinator | Switzerland |
| 2 | Naason Science Inc. | Partner | Korea, Republic of |
| 3 | Endotherm GmbH | Partner | Germany |
| 4 | Nucro-Technics, a Division of the Vimy Ridge Group Ltd. | Partner | Canada |
| 5 | Stichting Katholieke Universiteit - Radboud University Nijmegen | Partner | Netherlands |